EP Wealth Advisors LLC Has $210,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

EP Wealth Advisors LLC cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,944 shares of the medical equipment provider’s stock after selling 414 shares during the quarter. EP Wealth Advisors LLC’s holdings in Zimmer Biomet were worth $210,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. American Century Companies Inc. increased its position in shares of Zimmer Biomet by 12.6% during the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock worth $701,521,000 after acquiring an additional 722,041 shares in the last quarter. Equity Investment Corp acquired a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $70,104,000. Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of Zimmer Biomet by 49.1% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock valued at $189,161,000 after purchasing an additional 577,320 shares in the last quarter. Magnetar Financial LLC boosted its position in shares of Zimmer Biomet by 58.7% during the second quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock worth $142,203,000 after buying an additional 484,816 shares during the period. Finally, Van ECK Associates Corp raised its position in Zimmer Biomet by 12.4% in the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after buying an additional 411,163 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of recent research reports. Truist Financial upped their price target on Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a research report on Friday, November 1st. Wolfe Research assumed coverage on shares of Zimmer Biomet in a research report on Tuesday, September 10th. They issued a “peer perform” rating for the company. Canaccord Genuity Group cut their price target on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 10th. Wells Fargo & Company raised their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, Evercore ISI dropped their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $122.83.

Zimmer Biomet Trading Down 0.1 %

ZBH stock opened at $106.74 on Friday. The stock has a market cap of $21.25 billion, a price-to-earnings ratio of 20.29, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. The company has a fifty day moving average price of $107.69 and a two-hundred day moving average price of $108.70. Zimmer Biomet Holdings, Inc. has a one year low of $101.47 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.65 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.